Panel Discussion: Modernising Dermatology Trial Design: Reducing Placebo Noise, Updating Endpoints & Strengthening Site Execution
- Redesigning dermatology endpoints by addressing outdated scales, high placebo response, and the need for validated assessments in understudied diseases where current tools fail to capture meaningful patient change
- Improving trial integrity through stronger site strategy by prioritising dermatology-specific expertise, rigorous site preparation, and high-quality CRO oversight to minimise variability, reduce placebo inflation, and ensure reliable clinical evaluation
- Designing studies that reflect real-world dermatology by incorporating combination therapy considerations, cultural and behavioural adaptations, patient-centred outcomes, and feasible protocols that account for Europe’s fragmented healthcare pathways